A University of Colorado Cancer Center study published in the journal Pediatric Blood Cancers lays the scientific groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.
Researchers at The University of Kansas Cancer Center are working to fill the knowledge gap between DNA damage and cancer, including developing approaches to manipulate the DNA damage response to treat and prevent disease. Their research on an integral DNA repair protein was recently highlighted in the scientific journal, Nature Communications.
Intermountain Healthcare has endorsed the The National Comprehensive Cancer Network® (NCCN®) Imaging Appropriate Use Criteria (NCCN Imaging AUC™). Intermountain will aggregate the NCCN AUC for lung cancer with its own AUC and utilize the content for decision support.
Yale Cancer Center investigators have demonstrated in a new study that more sophisticated models to assess patient risk for cancer can result in better clinical trials with more definitive results.
The University of New Mexico Men’s and Women’s basketball teams will hold their ‘Lobos Love Pink’ games during the same week to raise awareness for breast cancer and to honor all those who face it. The games also raise awareness for breast cancer screening.
Progress in treating lung cancer has been enormous in the past 20 years according to a new review by researchers at Yale Cancer Center.
Two different proteins work separately as well as synergistically to feed a small pool of stem cells that help bladder cancer resist chemotherapy, research led by a Johns Hopkins Kimmel Cancer Center scientist suggests. The finding, published online in Cancer Research, could lead to new targets to fight this deadly disease and potentially other cancers as well.
Investigators at Rutgers Cancer Institute of New Jersey have developed a statistical method to identify patients with potential inherited, germline alterations in tumor suppressor genes while estimating gene loss in cancer cells through targeted genome sequencing.
New Mexico state legislators will divide along house lines in the end-of-session hotly contested basketball game Feb. 5. UNM Football Head Coach Bob Davie will coach the Senate "Lobos" and NMSU Football Head Coach Doug Martin will coach the House of Representatives "Aggies." But the real opponent is cancer.
Yale Cancer Center (YCC) has been awarded a $1 million grant by the Bristol-Myers Squibb Foundation (BSMF) to address health care disparities in cancer care and support.
Patients who developed bloodstream infections had significantly reduced microbiome diversity than patients who remained free of infection.
A new study in JNCCN finds majority of people with cancer would like their physicians to ask them where they would prefer to receive end-of-life care.
Rutgers Cancer Institute of New Jersey is now recognized as a Center of Excellence by the Myelodysplastic Syndromes (MDS) Foundation in the research, diagnosis and treatment of MDS disorders.
Among patients older than 80 years, 3.9 percent receiving surgery passed away within the 30-day post-treatment window, compared with 0.9 percent of patients receiving focused radiation.
According to Altmetric, which tracks the distribution and discussion of research papers online, a July article by several Yale physicians is the most-discussed paper ever published in the Journal of the National Cancer Institute (JNCI). The title of this blockbuster: “Use of Alternative Medicine for Cancer and Its Impact on Survival.”
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Patients who had no sign of disease at surgery after combination treatment did not progress to metastasis.
Columbia biomedical engineers design a new, biomaterials-based system that takes a soft approach to improving cell manufacturing and may bring new hope to cancer patients for T-cell therapy.
Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the 2018 Jessie Stevenson Kovalenko Medal for outstanding research in medical sciences, the National Academy of Sciences announced today.
Nonsmoking adolescents who use e-cigarettes, smokeless tobacco or tobacco water pipes are more likely to start smoking conventional cigarettes within a year, according to new research by UC San Francisco.
A discovery by scientists at Dana-Farber Cancer Institute and University of Texas Southwestern Medical Center presents drug developers with an entirely new tack in targeting one of the most-wanted molecular culprits in cancer.
Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients. Treatment is difficult because these tumors are often resistant to chemotherapy and lack actionable mutations commonly found in other types of melanoma that are targeted by specific drugs. However, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
.The University of Kansas today announced and celebrated a five-year nearly $25 million grant from the National Institutes of Health that will fund Frontiers: University of Kansas Clinical and Translational Science Institute (KU CTSI). This grant currently is the largest at the university, and the second-largest all time.
Two leading non-profits combine efforts to accelerate cancer immunotherapy clinical trials for patients globally
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have named Andrew M. Evens, DO, MSc, FACP as a new oncology leader responsible for the delivery of integrated cancer care across both entities in servicing the region. Dr. Evens, whose clinical expertise is in hematologic malignancies, most recently was the director of the Cancer Center at Tufts Medical Center in Boston.
Two research groups from Dana-Farber Cancer Institute have independently discovered a genetic mechanism in cancer cells that influences whether they resist or respond to immunotherapy drugs known as checkpoint inhibitors. The scientists say the findings reveal potential new drug targets and might aid efforts to extend the benefits of immunotherapy treatment to more patients and additional types of cancer.
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center.
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center.
In a commentary published in the Jan. 4 issue of the New England Journal of Medicine, UC Davis researcher William Murphy expressed cautious optimism about efforts to genetically engineer hematopoietic stem cells (HSCs) to temporarily resist cell death during transplantation. While these gene therapy approaches could dramatically improve patient outcomes, Murphy argues that their risks must be carefully studied in diverse models.
A $1 million grant from Gateway for Cancer Research will help Rutgers Cancer Institute of New Jersey Urologic Oncology Chief Isaac Yi Kim, MD, PhD, MBA evaluate the impact of surgically removing the prostate in men with metastatic prostate cancer in the United States and Asia.
A team from Roswell Park Cancer Institute has discovered a unique population of normal stem cells that may enable prostate cancer relapse. These findings may point the way toward strategies for treating or preventing prostate cancer recurrence.
A method developed by HHMI investigators sifts through hundreds of millions of potential targets to find a precise cancer beacon. The results may lead to better immunotherapies, which harness the immune system to attack tumors.
Researchers in Italy have discovered how specific versions of a protein called Numb protect the key tumor suppressor p53 from destruction. The study, which will be published December 21 in the Journal of Cell Biology, suggests that the loss of these particular Numb proteins makes breast cancers more aggressive and resistant to chemotherapy, but points the way toward new therapeutic approaches that could improve patient outcome by preserving p53 levels.
Many cancer cells are relatively sensitive to the deprivation of an essential amino acid known as methionine. Now, a Ludwig Cancer Research study published in the journal Science Signaling and led by Alex Toker, an investigator in the Ludwig Center at Harvard, has elucidated one mechanism behind that dependency.
Further enhancing a commitment to cutting-edge clinical research efforts, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health are welcoming Howard S. Hochster, MD, an internationally recognized leader in the development of cancer clinical trials and early phase cancer drugs.
University of Colorado Cancer Center study shows that radiosurgery may effectively treat brain metastases associated with certain types of lung cancer, even when the number of metastases exceeds established norms.
A new study in the Journal of the National Comprehensive Cancer Network highlights the need to improve access to stereotactic radiosurgery following radiotherapy to treat brain metastases for minority and lower-income populations.
Below is the December tip sheet from Fred Hutchinson Cancer Research Center. Story ideas include new research on leukemia therapies, racial disparities in end-of-life care, an experimental drug for pancreatic cancer and more.
“Roy Jensen, through his leadership and collaboration, has brought NCI (National Cancer Institute) designation to our town
Men infected with HPV16, the type responsible for most HPV-related cancers, are 20 times more likely to be reinfected with the same type of HPV after one year. That is according to a new study published this month in the Proceedings of the National Academy of Sciences. The article shows the same effect in both men who are sexually active and celibate, suggesting that they are not reacquiring the virus from another sexual partner.
Researchers at Rutgers Cancer Institute of New Jersey examined an association between mutational burden and response to immune checkpoint therapy in several cancer types and found that a mutational burden threshold exists in eight cancers that predict response to an immune checkpoint blockade.
Dr. Cheryl L. Willman of the University of New Mexico Comprehensive Cancer Center has been named a Fellow of the National Academy of Inventors (NAI).
When a targetable genetic alteration is present, matching the alteration with the appropriate targeted therapy is associated with a survival benefit of 1.5 years, regardless of smoking history.
In a new study in the journal Nature Communications, a research team from Roswell Park Cancer Institute reports their discovery of a major mechanism by which cells regulate the tumor suppressor p53, opening up new avenues for cancer research and treatment.
• Benjamin Ebert, MD, PhD, current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting • Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS)
New research by Yale Cancer Center (YCC) researchers shows a majority of pediatric cancer providers endorse the potential use of medical marijuana for children with advanced cancer, although providers who are legally eligible to certify its use are more cautious than those who aren’t.
• Azacitidine reverses resistance to SL-401 in AML and BPDCN cell lines, researchers find • Results prompt clinical trial of SL-401 and azacitidine in AML and MDS patients
Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .
Dr. Eunice Wang was invited to discuss results of a phase II clinical trial of crenolanib for adults with AML at the ASH 2017 annual meeting, and Dr. Kara Kelly, senior author of an oral abstract on outcomes disparities among children and adolescents with Hodgkin lymphoma.
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right